CHEMICAL MANAGEMENT

Intrinsic Viscosity Determation on IVS200 Automatic Viscometer (demonstrate)

June 13, 2022

In this video, we have demonstrated the intrinsic viscosity determination on IVS200 automatic viscometer.

Spotlight

IDEAYA Biosciences

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA’s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences.

OTHER VIDEOS

Chemical Screening Procedure: Glucocorticoid Signaling

video | May 26, 2022

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System - a 2 minute Preview of the Experimental Protocol...

Watch Now

New software to simulate crystal growth

video | May 25, 2022

In June 2021 we announced the winners of our first-ever set of Horizon Prizes. And in November we announced the winners of our new Horizon Prizes for Education....

Watch Now

Artificial Skin Helps Robots Sense Temperature, Pressure, and Chemical Compounds

video | June 2, 2022

A new artificial skin developed at Caltech can now give robots the ability to sense temperature, pressure, and even toxic chemicals through a simple touch....

Watch Now

Global Mining Flotation Chemicals Market | Industry Data Analytics

video | May 25, 2022

IndustryDataAnalytics Latest Published Global Mining Flotation Chemicals Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions....

Watch Now

Spotlight

IDEAYA Biosciences

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA’s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences.

Events